RxDoctor Payments Data

Chad Cleverly

Optometrist · Boise, IDNPI 1386660959

Payments from drug & device makers

$1,665in general payments, 2019–2025

Across 28 payments — averaging $59.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$774
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$168
  • Bausch & Lomb Americas Inc.$146
  • Kala Pharmaceuticals, Inc.$141
  • Optos, Inc.$123
  • Sun Pharmaceutical Industries Inc.$97
  • plus $218 from 6 others

What the payments were for

  • Consulting fees$55934%
  • Food & beverage$1,00160%
  • Entertainment$1056%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,665 in reported general payments places this provider in the 75th percentile of 304 optometrist providers in Idaho.

See all optometrist providers in Idaho

Medicare billing

Part B allowed, 2024
$46,192
Medicare patients
269
Services billed
616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine13$20,138
Loteprednol Etabonate25$3,510
Latanoprost125$776
Prednisolone Acetate15$439
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha27$304
ErythromycinErythromycin Base12$134
Timolol Maleate43$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$75$20,13813 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$168$3,51025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 304 optometrist providers in Idaho.

Other optometrist in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →